Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer ’s disease (AD) - other company programmes in AD continue

- Roche today announced the decision to discontinue CREAD I and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early (prodromal to mild) sporadic Alzheimer ’s disease (AD). The decision was based on the results of a pre-planned interim analysis assessing the safety and efficacy of crenezumab conducted by the Independent Data Monitoring Committee, which indicated that crenezumab was unlikely to meet the primary endpoint of change from baseline in Clin ical Dementia Rating-Sum of Boxes (CDR-SB) Score. No safety signals for crenezumab were observed in this analysis and the overall safety profile was similar to that seen in previous trials.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news